Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $225 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $225.

November 29, 2023 | 9:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst reaffirms a Buy rating on Jazz Pharmaceuticals with a $225 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a reputable analyst like Ami Fadia from Needham, along with the maintenance of a high price target ($225), suggests a strong vote of confidence in Jazz Pharmaceuticals. This endorsement is likely to be viewed positively by investors and could lead to a short-term increase in the stock price, assuming market conditions do not change significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100